Alan L. Leggett
- Molecular Biology top 10%
- Ubiquitin and proteasome pathways 3
- Protein Degradation and Inhibitors 3
- DNA Repair Mechanisms 2
- Oncology top 10%
- Cancer-related Molecular Pathways 2
- PARP inhibition in cancer therapy 2
- CAR-T cell therapy research 1
- Hematology top 10%
-
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 2
- Occupational and environmental lung diseases 2
- Co-authors
- Nathanael S. GrayBehnam NabetDennis L. BuckleyJames E. BradnerJoshiawa PaulkKwok‐Kin WongAmanda SouzaJennifer A. Perry
- Cited by
- Molecular BiologyOncologyHematology
- Journals
- Cell chemical biology (2 papers)Cancer Cell (1 paper)Journal of Medicinal Chemistry (1 paper)
- Partner nations
- United StatesGermanyChina
In The Last Decade
Alan L. Leggett
8 papers receiving 1.2k citations
Hit Papers
Peers
Comparison fields: 5 of 62
- Molecular Biology 1.1k
- Oncology 365
- Hematology 91
- Cell Biology 61
- Pulmonary and Respiratory Medicine 120
Countries citing papers authored by Alan L. Leggett
This map shows the geographic impact of Alan L. Leggett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan L. Leggett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan L. Leggett more than expected).
Fields of papers citing papers by Alan L. Leggett
This network shows the impact of papers produced by Alan L. Leggett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan L. Leggett. The network helps show where Alan L. Leggett may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Alan L. Leggett, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 163 | |
| 2 | 2020 | 36 | |
| 3 | 2019 | 115 | |
| 4 | The dTAG system for immediate and target-specific protein degradationbreakdown → | 2018 | 652 |
| 5 | 2018 | 96 | |
| 6 | 2018 | 115 | |
| 7 | 2017 | 13 | |
| 8 | 2015 | 44 |
About Alan L. Leggett
Alan L. Leggett is a scholar working on Immunology and Allergy, Oncology and Molecular Biology, having authored 8 papers that have together received 1.2k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (3 papers), Protein Degradation and Inhibitors (3 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers), DNA Repair Mechanisms (2 papers), Cancer-related Molecular Pathways (2 papers), Occupational and environmental lung diseases (2 papers), PARP inhibition in cancer therapy (2 papers) and CAR-T cell therapy research (1 paper). The work is most often cited by research in Molecular Biology (1.1k citations), Oncology (365 citations) and Hematology (91 citations). Alan L. Leggett has collaborated with scholars based in United States, Germany and China. Frequent co-authors include Nathanael S. Gray, Behnam Nabet, Dennis L. Buckley, James E. Bradner, Joshiawa Paulk, Kwok‐Kin Wong, Amanda Souza, Jennifer A. Perry, Matthew A. Lawlor and Michael A. Erb. Their work appears in journals such as Cell chemical biology, Cancer Cell, Journal of Medicinal Chemistry, Nature Chemical Biology and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.